Research programme: antioxidant inflammation modulators - Reata Pharmaceuticals/AbbVie

Drug Profile

Research programme: antioxidant inflammation modulators - Reata Pharmaceuticals/AbbVie

Alternative Names: AIMs - Reata/Abbott; CDDO-Im; RTA 403; RTA 404; RTA dh404; RTA-411; Synthetic triterpenoids - Reata/Abbott; TBEs - Reata/Abbott; Tricyclic bis-enones - Reata/Abbott

Latest Information Update: 01 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer AbbVie; Reata Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Ketones; Triterpenes
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Chronic obstructive pulmonary disease; Neurological disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 12 Dec 2011 Reata and Abbott Laboratories agree to co-develop and co-promote synthetic triterpenoids worldwide
  • 09 Mar 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top